Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason score

Prostate

Volumn 59, Issue 4, 2004, Pages 436-439

  Hajdinjak, Tine ^a   Zagradišnik, Boris ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Case control studies; Genetic predisposition to disease; Glucuronosyltransferase; Polymorphism; Prostate neoplasms; Single nucleotide

Indexed keywords

ANDROSTANOLONE; GLUCURONOSYLTRANSFERASE;

AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA POLYMORPHISM; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; UGT2B15 GENE;

AGED; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS;

EID: 2442716351     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20024     Document Type: Article

References (16)

1. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology 2001;57:205-212.
2. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-347.
3. MacLeod SL, Nowell S, Plaxco J, Lang NP. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000;7:777-782.
4. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M. A polymorphism in the UDP-glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:497-498.
5. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
6. Barbier O, Lapointe H, El Alfy M, Hum DW, Belanger A. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 2000;85:4819-4826.
7. Kanaya J, Takashima M, Koh E, Namiki M. Androgen-independent growth in LNCaP cell lines and steroid uridine diphosphate-glucuronosyltransferase expression. Asian J Androl 2003;5:9-13.
8. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997;7:317-325.
9. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M III, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. Oncology (Huntingt) 2000;14:111-119.
10. Hawhins JR. Finding mutations: The basics. New York: Oxford University Press; 1997.
11. Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology 2001;57:4-27.
12. Ross RK. The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Sci Publ 2001;154:207-213.
13. Nelson WG, Wilding G. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology 2001;57:56-63.
14. Lampe JW, Bigler J, Bush AC, Potter JD. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev 2000;9:329-333.
15. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F. EAU guidelines on prostate cancer. Eur Urol 2001;40:97-101.
16. George N. Therapeutic dilemmas in prostate cancer: Justification for watchful waiting. Eur Urol 1998;34(Suppl 3):33-36.